Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Evercore ISI Group Maintains In-Line on Moderna, Maintains $120 Price Target

Author: Benzinga Newsdesk | June 27, 2024 08:13am
Evercore ISI Group analyst Cory Kasimov maintains Moderna (NASDAQ:MRNA) with a In-Line and maintains $120 price target.

Posted In: MRNA